Centogene NV gains as more COVID-19 testing lifts Q2 revenue

Crown LiquidationCo NV in liquidatie

07/09/2021 14:12

** U.S.-listed shares of Germany-based diagnostic and pharma
co  CNTG.O  up 11% at $11.70 premarket
    ** Co's Q2 rev surged 434% y-o-y to 51.9 mlon euros ($61.51
mln), beating Refinitiv est of 41.36 mln euros helped by
increase in diagnostic sales and commerical COVID-19 testing
 urn:newsml:reuters.com:*:nGNX4YWrjv
    ** Clinical diagnostics rev (excl. COVID) increased 82% to
6.7 mln euros in Q2, while rev from commercial COVID-19 testing
was 42.3 mln euros, up from 2.1 mln euros in year-ago qtr
    ** CNTG continues to see recovery in diagnostics segment;
anticipates COVID-19 rev to decline in H2, but forecasts overall
revenue for FY21 to surpass FY20 rev of 128.38 mln euros
    ** Street expects FY21 rev of 143.98 mln euros - Refinitiv
data
    ** However, co posts wider-than-expected Q2 loss of 0.37
euros/shr
    ** As of last close, stock had fallen 2.2% YTD


($1 = 0.8437 euros)

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))